The new genes identified are far more common in the population than the well-known BRCA1 and BRAC2, but carry a lower risk. Between 50% and 85% of women with BRCA1 or BRCA2 will develop breast cancer in their lifetime. In comparison, about 14% of women with one of the new genes would develop breast cancer.